LIMERICK, Pa.--(BUSINESS WIRE)--Apr. 22, 2013--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
devices for critical care and surgery, will showcase its interventional
access portfolio at the 8th International Congress on Vascular Access
(“VAS”) to be held in Prague, Czech Republic on April 25-27, 2013.
During the event, the Company will highlight its Arrow chronic
hemodialysis catheter portfolio, which offers both split-tip and
step-tip catheters for both retrograde and antegrade insertion
techniques.
The latest member, the Arrow NextStep® Retrograde or Antegrade product
family, consists of step-tip catheters that can easily be inserted and
tunneled using retrograde or antegrade technique respectively, combined
with the advantage of split-tip high flow characteristics. The unique
tip is designed for smooth, over-the-wire transitions during catheter
insertions and exchanges.
The Arrow Cannon® II Plus and the Arrow Edge® products are split-tip
catheters that can be tunneled retrograde or antegrade, respectively.
The Company will also give special attention to the role of
chlorhexidine in Teleflex vascular access products and the Arrow+gard®
antimicrobial technology's ability to reduce catheter related blood
infections.1
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a
range of procedures in critical care and surgery. Our mission is to
provide solutions that enable healthcare providers to improve outcomes
and enhance patient and provider safety. Headquartered in Limerick, PA,
Teleflex employs approximately 11,600 people worldwide and serves
healthcare providers in more than 140 countries. Additional information
about Teleflex can be obtained from the company's website at teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, Arrow, Arrow+gard, NextStep, Cannon and Arrow Edge are trade
marks or registered trademarks of Teleflex Incorporated or its
affiliates. ©2013 Teleflex Incorporated. All rights reserved.
References:
1 Veenstra, D.L., Saint, S., Saha, S., Lumley,
T.,Sullivan, S.D. “Cost-Effectiveness of Antiseptic-Impregnated Central
Venous Catheters for the Prevention of Catheter-Related Bloodstream
Infection.” Journal of the American Medical Association, January 20,
1999, Vol. 281, Issue 3, pp. 261–267.
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836
or
Martina
Teichmann-Zindler
Director Marketing Communications International
+49
(0)7151-406-538
martina.teichmann@teleflex.com